Smith et al.4444 Smith RD, Levy P, Ferrario CM; Consideration of Noninvasive Hemodynamic Monitoring to Target Reduction of Blood Pressure Levels Study Group. Value of noninvasive hemodynamics to achieve blood pressure control in hypertensive subjects. Hypertension. 2006;47(4):771-7.
|
164 |
Multicenter, randomized |
After 3 months, a higher reduction in blood pressure was observed in the treatment group guided by ICG, 55% vs. 27%; OR 2.32 (1.27-5.35), p = 0.007 |
Taler et al.4545 Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension. 2002;39(5):982-8.
|
104 |
Single-center, randomized |
After 3 months, 56% of the individuals in the ICG-based approach to hypertension achieved blood pressure < 140/90 mmHg vs. 18 (33%); OR 2.55 (1.15-5.64); p = 0.02 |
Sramek et al.5454 Sramek BB TJ, Hojerov M, Cervenka V. Normohemodynamic goal -oriented antihypertensive therapy improves the outcome. [abstract]. In: 11th Scientific Meeting, New York (NY), 1996. Am J Hypertens. 1996;9:141A.
|
322 |
Single-center prospective, non-randomized |
After 3 weeks of ICG-based therapy, 63% of patients became normotensive; success rate of 58-68% |
Sharman et al.5555 Sharman DL, Gomes CP, Rutherford JP. Improvement in blood pressure control with impedance cardiography-guided pharmacologic decision making. Congest Heart Fail. 2004;10(1):54-8.
|
21 |
Single-center, prospective, non-randomized |
After 7 months, 57% of patients with resistant hypertension had BP control (blood pressure <140/90 mmHg); p < 0.001 |
Krzesinski et al.5656 Krzesinski P, Gielerak G, Kowal J, Piotrowicz K. Usefulness of impedance cardiography in optimisation of antihypertensive treatment in patients with metabolic syndrome: a randomised prospective clinical trial. Kardiol Pol. 2012;70(6):599-607.
|
82 |
Single-center, randomized |
After 3 months, more patients in the ICG-guided group achieved BP control in both ABPM (23.5 vs. 43.9%, p = 0.117) and OBPM (23.5 vs. 36.6%, p = 0.22) |
Krzesinski et al.5757 Krzesinski P, Gielerak GG, Kowal JJ. A "patient-tailored" treatment of hypertension with use of impedance cardiography: a randomized, prospective and controlled trial. Med Sci Monit. 2013 Apr 5;19:242-50.
|
128 |
Single-center, randomized |
After 3 months, all blood pressure values were lower in the ICG-guided treatment group, with statistical significance in OBPM and nocturnal blood pressure (p < 0.05) |
Krzesinski et al.5858 Krzesinski P, Gielerak G, Stanczyk A, Piotrowicz K, Skrobowski A. Who benefits more from hemodynamically guided hypotensive therapy? The experience from two randomized, prospective and controlled trials. Ther Adv Cardiovasc Dis. 2016;10(1):21-9.
|
272 |
Single-center, randomized |
After 3 months, final BP values were significantly lower in the ICG-guided treatment group for OBPM (p = 0.01), especially in patients with higher blood pressure (p = 0.003) |
Krzesinski et al.5959 Krzesinski P, Gielerak G, Stanczyk A, Piotrowicz K, Uzieblo-Zyczkowska B, Banak M, et al. The effect of hemodynamically-guided hypotensive therapy in one-year observation: randomized, prospective and controlled trial (FINEPATH study). Cardiol J. 2016;23(2):132-40.
|
144 |
Single-center, randomized |
After 12 months, the final blood pressure values were lower in the ICG-guided treatment group, with a BP reduction of at least 20 mmHg in the office measurements of diastolic pressure (27.3% vs. 12.1%; = 0.034), 24-hour mean systolic blood pressure (49.1% vs. 27.3%, p = 0.013) and improvement in left ventricular diastolic dysfunction (delta E/A 0.34 vs. 0.12; = 0.017). |